DK200100444A - Farmaceutisk formulering samt anvendelse heraf til fremstilling af et middel til behandling af kredsløbssygdomme. - Google Patents

Farmaceutisk formulering samt anvendelse heraf til fremstilling af et middel til behandling af kredsløbssygdomme. Download PDF

Info

Publication number
DK200100444A
DK200100444A DK200100444A DKPA200100444A DK200100444A DK 200100444 A DK200100444 A DK 200100444A DK 200100444 A DK200100444 A DK 200100444A DK PA200100444 A DKPA200100444 A DK PA200100444A DK 200100444 A DK200100444 A DK 200100444A
Authority
DK
Denmark
Prior art keywords
pharmaceutical formulation
treatment
preparation
agent
well
Prior art date
Application number
DK200100444A
Other languages
English (en)
Inventor
Svendsen Hans Ole
Original Assignee
M B Pharmos Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by M B Pharmos Aps filed Critical M B Pharmos Aps
Priority to DK200100444A priority Critical patent/DK174072B1/da
Priority to DE60202446T priority patent/DE60202446T8/de
Priority to ES02704637T priority patent/ES2236487T3/es
Priority to AT02704637T priority patent/ATE285784T1/de
Priority to PCT/DK2002/000177 priority patent/WO2002074319A1/en
Priority to EP02704637A priority patent/EP1368046B1/en
Application granted granted Critical
Publication of DK174072B1 publication Critical patent/DK174072B1/da
Publication of DK200100444A publication Critical patent/DK200100444A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/51—Gentianaceae (Gentian family)
    • A61K36/515—Gentiana
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Description

PATENTKRAV 1. Farmaceutisk formulering, kendetegnet ved, at den som aktive bestanddele omfatter capsaicin, curcumin og ensian. 2. Formulering ifølge krav 1,kendetegnet ved, at den omfatter en daglig dosis på 0,2 - 2,0 mg capsaicin. 3. Formulering ifølge krav 2, kendetegnet ved, at den omfatter en daglig dosis på 0,5 - 1,5 mg capsaicin. 4. Formulering ifølge krav 1,kendetegnet ved, at den omfatter en daglig dosis på 5 - 20 mg curcumin. 5. Formulering ifølge krav 4, kendetegnet ved, at den omfatter en daglig dosis på 7 - 15 mg curcumin. 6. Formulering ifølge krav 1,kendetegnet ved, at den omfatter en daglig dosis på 100 - 500 mg ensianrod. 7. Formulering ifølge krav 6, kendetegnet ved, at den omfatter en daglig dosis på 200 - 400 mg ensianrod. 8. Formulering ifølge krav 1,kendetegnet ved, at den endvidere omfatter vanillin. 9. Formulering ifølge krav 8, kendetegnet ved, at den omfatter en daglig dosis på 0,2 - 1,5 mg vanillin. 10. Formulering ifølge krav 9, kendetegnet ved, at den omfatter en daglig dosis på 0,3 - 1,3 mg vanillin. 11. Formulering ifølge krav 8, kendetegnet ved, at den omfatter en daglig dosis på 75-125 mg formalet spansk rød peber 15-25 mg vanilje 250-350 mg formalet ensianrod 450-550 mg formalet gurkemejerod. 12. Formulering ifølge ethvert af de foregående krav, kendetegnet ved, at den endvidere omfatter et eller flere konventionelle hjælpestoffer valgt blandt fyldstoffer, smøremidler, bindemidler, desintegreringsmidler, farvestoffer og aromastoffer. 13. Anvendelse af en formulering ifølge ethvert af kravene 1-12 til fremstilling af et middel til behandling af hjertekredsløbssygdomme. 14. Anvendelse af en formulering ifølge ethvert af kravene 1-13 til fremstilling af et middel til behandling af kolesterolubalance.
DK200100444A 2001-03-15 2001-03-15 Farmaceutisk formulering samt anvendelse heraf til fremstilling af et middel til behandling af kredsløbssygdomme. DK174072B1 (da)

Priority Applications (6)

Application Number Priority Date Filing Date Title
DK200100444A DK174072B1 (da) 2001-03-15 2001-03-15 Farmaceutisk formulering samt anvendelse heraf til fremstilling af et middel til behandling af kredsløbssygdomme.
DE60202446T DE60202446T8 (de) 2001-03-15 2002-03-15 Pharmazeutische formulierung und ihre verwendung für die herstellung eines medikaments zur behandlung von herz-kreislauf-erkrankungen
ES02704637T ES2236487T3 (es) 2001-03-15 2002-03-15 Formulacion farmaceutica y su uso para preparar un medicamento para el tratamiento de enfermedades cardiovasculares.
AT02704637T ATE285784T1 (de) 2001-03-15 2002-03-15 Pharmazeutische formulierung und ihre verwendung für die herstellung eines medikaments zur behandlung von herz-kreislauf-erkrankungen
PCT/DK2002/000177 WO2002074319A1 (en) 2001-03-15 2002-03-15 Pharmaceutical formulation and the use thereof for preparing a medicament for the treatment of cardiovascular diseases
EP02704637A EP1368046B1 (en) 2001-03-15 2002-03-15 Pharmaceutical formulation and the use thereof for preparing a medicament for the treatment of cardiovascular diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK200100444 2001-03-15
DK200100444A DK174072B1 (da) 2001-03-15 2001-03-15 Farmaceutisk formulering samt anvendelse heraf til fremstilling af et middel til behandling af kredsløbssygdomme.

Publications (2)

Publication Number Publication Date
DK174072B1 DK174072B1 (da) 2002-05-21
DK200100444A true DK200100444A (da) 2002-05-21

Family

ID=8160371

Family Applications (1)

Application Number Title Priority Date Filing Date
DK200100444A DK174072B1 (da) 2001-03-15 2001-03-15 Farmaceutisk formulering samt anvendelse heraf til fremstilling af et middel til behandling af kredsløbssygdomme.

Country Status (6)

Country Link
EP (1) EP1368046B1 (da)
AT (1) ATE285784T1 (da)
DE (1) DE60202446T8 (da)
DK (1) DK174072B1 (da)
ES (1) ES2236487T3 (da)
WO (1) WO2002074319A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339101B (es) 2011-03-11 2016-05-11 Jose Arturo Castañeda Miranda Polifarmaco herbario para la prevencion y el tratamiento de la ateroesclerosis.
US10092550B2 (en) 2014-10-21 2018-10-09 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof
US9907786B2 (en) 2014-10-21 2018-03-06 Ions Pharmaceutical S.À R.L. Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof
US20160106722A1 (en) 2014-10-21 2016-04-21 Life Plus, LLC Human therapeutic agents
CN107496849A (zh) * 2017-10-11 2017-12-22 湖南中医药大学 一种治疗冠心病的药物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0739350B2 (ja) * 1990-08-03 1995-05-01 ゼリア新薬工業株式会社 生薬配合チュアブル錠
US6440464B1 (en) * 1996-06-10 2002-08-27 Viva Life Science Nutritive composition for cardiovascular health containing fish oil, garlic, rutin, capsaicin, selenium, vitamins and juice concentrates
CN1209281A (zh) * 1998-07-30 1999-03-03 李树春 月苋草花茶

Also Published As

Publication number Publication date
DE60202446D1 (de) 2005-02-03
DK174072B1 (da) 2002-05-21
EP1368046A1 (en) 2003-12-10
ATE285784T1 (de) 2005-01-15
EP1368046B1 (en) 2004-12-29
DE60202446T8 (de) 2006-08-24
WO2002074319A1 (en) 2002-09-26
DE60202446T2 (de) 2006-01-12
ES2236487T3 (es) 2005-07-16

Similar Documents

Publication Publication Date Title
Chaturvedi Uses of turmeric in dentistry: An update
BR0214962A (pt) Composição para tratar distúrbios neurocerebrovasculares
WO2003013428A3 (en) Nutritional supplements and methods of using same
BR0008699A (pt) Combinações de formoterol e furoato demometasona para asma
RU2002123048A (ru) Улучшенная растительная композиция, обладающая противоаллергическими свойствами, и способ ее получения
JP2017506241A (ja) ウコンならびにホソババレンギクの抽出物を含有する、末梢性炎症ならびに疼痛の軽減に有用な組成物
Hoffman Ginger: an ancient remedy and modern miracle drug.
Mahnashi et al. Venlafaxine demonstrated anti-arthritic activity possibly through down regulation of TNF-α, IL-6, IL-1β, and COX-2
TNSN05131A1 (en) New synergistic combination comprising roflumilast and formoterol
DK200100444A (da) Farmaceutisk formulering samt anvendelse heraf til fremstilling af et middel til behandling af kredsløbssygdomme.
WO2004014367A3 (en) Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer's disease
WO2001076601A3 (en) Pharmaceutical compositions comprising salmeterol and ipratropium
EP1393738A4 (en) MEDICINE AGAINST DIABETES
WO2003018535A3 (en) Novel aminobenzoephenones
WO2003011230A3 (en) Modified reoviral therapy
McKnight et al. 7.4 HIV and complementary medicine
WO2003013655A3 (en) Carbonic anhydrase inhibitors
UA4698U (uk) Засіб для лікування проктологічних захворювань - фітокрем "домашній цілитель"
Ajayan et al. Scientific Rationale for the Use of Single Herb Remedies in Ayurveda
Singla et al. Traditional Health Boosters: Onion, Ginger and Garlic
WO2023091111A1 (en) Ace-2 enzyme inhibitory effects of essential oils obtained from the aerial parts of eucalyptus globulus and eucalyptus citriodora plants
CN116492444A (zh) 一种用于改善多种亚健康症状的中药组合物及其制备方法
CN104645240B (zh) 一种中药止痛制剂及其制备方法
WO2000002578A8 (fr) Remedes contre les maladies liees a l'apoptose
Zhili et al. Studies on the effect of ethanol extracts of 56 traditional Chinese drugs on the activity of tyrosinase

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed

Ref document number: DK